Broyhill Asset Management Invests $3.41 Million in Fresenius Medical Care AG (NYSE:FMS)

Broyhill Asset Management purchased a new stake in Fresenius Medical Care AG (NYSE:FMS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 150,686 shares of the company’s stock, valued at approximately $3,412,000. Fresenius Medical Care makes up approximately 3.0% of Broyhill Asset Management’s portfolio, making the stock its 10th largest position.

A number of other large investors have also recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC increased its holdings in Fresenius Medical Care by 192.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after buying an additional 806 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Fresenius Medical Care in the 3rd quarter valued at approximately $38,000. Russell Investments Group Ltd. raised its position in shares of Fresenius Medical Care by 234.1% during the 4th quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company’s stock valued at $71,000 after acquiring an additional 2,208 shares in the last quarter. Jones Financial Companies Lllp lifted its stake in Fresenius Medical Care by 80.5% during the fourth quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock worth $102,000 after purchasing an additional 2,012 shares during the last quarter. Finally, Venturi Wealth Management LLC boosted its holdings in Fresenius Medical Care by 8.4% in the fourth quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company’s stock worth $129,000 after purchasing an additional 441 shares during the period. 8.37% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

FMS has been the topic of a number of recent research reports. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Truist Financial lifted their target price on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Monday, January 6th.

Fresenius Medical Care Stock Up 0.6 %

Fresenius Medical Care stock opened at $23.96 on Monday. The firm has a market capitalization of $14.06 billion, a P/E ratio of 19.80, a P/E/G ratio of 0.76 and a beta of 0.93. The company has a 50-day simple moving average of $23.94 and a 200-day simple moving average of $22.79. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $25.96. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.